bpc-157 human clinical trials back pain BPC-157: The Secret Weapon for Injury Repair & Gut Health | Desert Mobile Medical bpc-157 human clinical trials back
Description
doi: 10.1073/pnas.94.9.4620
Bioconjug Chem
Research demonstrates BPC-157 increases mesenchymal cell recruitment with periosteum reactivation occurring within 3 days of treatment initiation, establishing conditions favorable for rapid bone repair
A 2022 dose-response RCT (Yi et al., Geroscience) at 300/600/900 mg/day raised NAD+ dose-dependently with no safety issues at 60 days
